mrepo:46draft

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revisionBoth sides next revision
mrepo:46draft [06/12/2019 @ 15:10] – [Insight 46] adammooremrepo:46draft [06/12/2019 @ 15:14] – adammoore
Line 33: Line 33:
   *  {{Medication.pdf|Medication}} usage   *  {{Medication.pdf|Medication}} usage
   *  Cognitive test results - including {{ad8.pdf|ad8}}, {{mci.pdf|mci}}, {{scd_mycog.pdf|scd and MyCog}}, {{mmse.pdf|mmse}} and others    *  Cognitive test results - including {{ad8.pdf|ad8}}, {{mci.pdf|mci}}, {{scd_mycog.pdf|scd and MyCog}}, {{mmse.pdf|mmse}} and others 
-  *  {{Audiometry.pdf|Audiometry}}+  *  {{Audiometry.pdf|Audiometry}}  
 \\ \\  \\ \\ 
 ---- ----
-Insight 46 was funded by Alzheimer’s Research UK, MRC Dementias Platform UK, The Wolfson Foundation, Weston Brain Institute, Brain Research UK, and British Heart Foundation. The 18F Florbetapir amyloid PET tracer was provided by AVID Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly+Insight 46 was funded by Alzheimer’s Research UK, MRC Dementias Platform UK, The Wolfson Foundation, Weston Brain Institute, Brain Research UK, and British Heart Foundation. The 18F Florbetapir amyloid PET tracer was provided by AVID Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly.